Press coverage about DelMar Pharmaceuticals (NASDAQ:DMPI) has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. DelMar Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.5157045398565 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 29th.
Shares of DelMar Pharmaceuticals (DMPI) opened at $1.40 on Monday. DelMar Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $5.39. The stock has a market cap of $30.24, a price-to-earnings ratio of -2.06 and a beta of 1,227.20.
DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). equities research analysts anticipate that DelMar Pharmaceuticals will post -0.54 earnings per share for the current year.
In other DelMar Pharmaceuticals news, CEO Saiid Zarrabian bought 60,900 shares of the stock in a transaction dated Tuesday, November 14th. The shares were bought at an average cost of $0.82 per share, for a total transaction of $49,938.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
ILLEGAL ACTIVITY WARNING: “DelMar Pharmaceuticals (DMPI) Given Daily News Impact Score of 0.12” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/22/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-delmar-pharmaceuticals-dmpi-stock-price.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.